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(57) ABSTRACT 
Aveterinary composition comprising a guanidine derivative, 
e.g., guanabenZ or guanabenZ acetate is provided Which 
produces a rapid acting and long lasting sedative and anal 
gesic effect in a subject animal that is selectively reversible. 
The use of guanabenz in the horse provides for a safe, 
effective, long lasting and rapidly reversible sedative and 
analgesic Which can be used on the standing animal. Meth 
ods of use of the compositions of the invention are also 
provided. 
15 Claims, 2 Drawing Sheets 
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LONG ACTING, REVERSIBLE VETERINARY 
SEDATIVE AND ANALGESIC AND METHOD 
OF USE 
This application claims the bene?t of priority in US. 
Provisional Application Ser. No. 60/206,625, ?led on May 
24, 2000. 
FIELD OF INVENTION 
The present invention relates to the ?eld of veterinary 
medicine and to compositions and methods of use for rapid 
acting reversible sedatives, tranquilizers and analgesics in 
animals. In particular, the present invention relates to a rapid 
acting reversible sedative and analgesic having 0t adrenergic 
agonist activity that is adapted for use in the standing 
animal. 
BACKGROUND OF THE INVENTION 
Veterinary medicine and especially in large animal prac 
tice, e.g., equine and bovine medicine and surgery, has 
incorporated various diagnostic, therapeutic and surgical 
procedures into the daily routine of the large animal prac 
titioner. Many of these procedures are greatly facilitated and 
can be accomplished in the standing animal if the animal 
remains clam, motionless, and virtually pain free. An addi 
tional consideration is that it may also be bene?cial to calm 
the animal, e.g., the coW or horse, before bringing it into 
proximity of expensive equipment or to minimiZe the poten 
tial for human injury. 
Commonly used are sedatives Which have a calming 
effect and tranquiliZers Which are a class of drugs used in the 
treatment of anxiety states. The goal of sedative and tran 
quiliZer administration is to eliminate fear, produce a calm 
ing effect, reduce resistance to manipulation, and, to the 
extent there is an analgesic effect of the drug, to ideally 
eliminate pain. Generally, users or user facilities of such 
sedatives, tranquiliZers and analgesics are veterinary hospi 
tals, veterinarians Working under ?eld conditions, animal 
control facilities, humane societies, Zoos, researchers and 
the like. 
Classically, sedatives are a distinct groups of drugs based 
on their central nervous system (CNS) site of action. Seda 
tives are classically considered as agents that act at the 
cortical level and, if given in suf?cient quantities, Will 
produce CNS depression to the point of hypnosis (arti?cial 
sleep). TranquiliZers act at the sub-cortical levels, particu 
larly at the reticular activating system, effectively ?ltering 
afferent and efferent nervous system activity. Increasing 
doses of tranquiliZers produce greater degrees of calming 
but do not produce hypnosis. In practical use in animals, 
drugs acting at different levels of the CNS have been used 
to obtain the same result, thus the distinction often has 
become blurred and the term sedative-tranquiliZer has 
evolved. 
Alpha-2-adreno receptor agonists produce sedation, 
muscle relaxation and analgesia When administered intrave 
nously or intramuscularly. Alpha-2-adreno receptor agonists 
are used to provide standing chemical restraint for various 
procedures, to provide analgesia, and to act as sedatives 
prior to anesthesia. The most commonly used alpha-2 
agonists used, e.g., in the horse, are xylaZine, detomidine 
and romi?dine. All produce dose-dependent sedation and 
muscle relaxation Whereas only xylaZine and detomidine 
possess analgesic properties. The duration of action of these 
alpha-2-adreno receptor agonists, hoWever is typically short, 
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e.g., a single intravenous administration of 300 mg of 
xylaZine in an adult horse produces moderate sedation and 
analgesia lasting from betWeen about 30 to about 60 min 
utes. Therefore, there exists a need in the art for a long acting 
sedative and analgesic Which can produce profound sedation 
and analgesia for longer periods of time folloWing a single 
administration of the active. 
Upon administration of the alpha-2-agonists, horses typi 
cally assume a Wide stance With the head extended and 
loWered (ptosis). In male horses, some relaxation of the 
penis may occur and the loWer lip becomes ?accid. Muscle 
relaxation and ataxia may be severe, particularly When large 
doses are administered. The effects of alpha-2-adreno recep 
tor agonists can be speci?cally antagoniZed (reversed) by the 
administration of and alpha-2-adreno receptor antagonist 
(Hubbell J. A. E. and Muir W. W. Standing Chemical 
Restraint p. 1874192 in Equine Internal Medicine by Reed 
S. M and Bayly W. M, 1997) 
Central alpha-2-adrenergic agonist cross the blood-brain 
barrier and stimulate alpha-2-adrenergic receptors in the 
vasomotor region of the brainstem. Stimulation Of these 
receptors decreases sympathetic tone, brain turnover of 
norepinephrine and central sympathetic out?oW and activity 
of the preganglionic sympathetic nerves. The net effect is a 
reduction in norepinephrine release. Central alpha-2-adren 
ergic agonist may also stimulate the peripheral alpha-2 
adrenergic receptors that mediate vasoconstriction. The 
usual physiologic effect is a decrease in peripheral resistance 
and sloWing of the heart rate; hoWever, output is either 
unchanged or mildly decreased. Preservation of cardiovas 
cular re?exes prevents postural hypertension. 
In human medicine, a variety of guanidine derivatives 
have been used clinically as anti-hypertensive agents, 
including clonidine, guanabenZ, guanacline, guanadrel, gua 
naZodine, guanethidine, guanfacine and guanochlor, guan 
oxabenZ and guanoxan. 
GuanabenZ (l-[2,6-dichlorobenZylidine-amino]-3-guani 
dine) is an anti-hypertensive drug Whose mechanism of 
action is an agonistic stimulatory effect of the central alpha-2 
adrenergic receptors in the cardiovascular regulatory centers 
in the brainstem and spinal cord. Its therapeutic effects in 
humans include a reduction in sympathetic tone (a reduction 
in heart rate and cardiac output), an increase in parasympa 
thetic tone (a reduction in heart rate and cardiac output) and 
vasodilation (a relaxation of capacitance vessels and reduc 
tion in total peripheral resistance). GuanabenZ is currently 
marketed in human medicine in the general class of medi 
cines called antihypertensives. It is used to treat high blood 
pressure (hypertension). GuanabenZ acetate is available on 
the market as 4 and 8 mg tablets to be taken orally, e.g., as 
WYTENSIN® (Wyeth-Ayerst, Alexandria, Va.) 
Certain uses of guanabenZ have been previously disclosed 
in the art. For example, US. Pat. No. 4,060,640, to Kodama 
et al., describes guanabenZ, and its related compounds, as 
being central nervous system depressants that reduce hyper 
excitability and induce sedation, overcoming psychic 
depression in humans. 
US. Pat. No. 5,958,933 to Naftchi discloses guanabenZ, 
as part of a drug combination, as being a neurologically 
active compound that When administered in an appropriate 
dosage amount is suf?cient to restore neurological function 
or control spasticity in humans suffering from injury to the 
central nervous system. 
US. Pat. No. 4,742,054 to Naftchi discloses guanabenZ to 
have a restorative effect on the central nervous system, 
especially in the treatment in mammals of motor and sensory 
functional losses due to the traumatic injury to the spinal 
US 7,074,834 B2 
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cord. GuanabenZ is described as being an effective anaes 
thetic compound and for use in a method for treating a 
mammal having a damaged central nervous system. 
US. Pat. No. 5,635,204 to GevirtZ et al. discloses gua 
nabenZ, in combination With other drugs at a particular 
dosage as being an effective anaesthetic. 
US. Pat. No. 5,958,933, to Naftchi describes oral over 
dosage of guanabenZ, as not being reported to result in 
anesthesia; the incidents Were recorded as hypotension, 
somnolence, lethargy, irritability, myosis and bradycardia in 
young children. 
In veterinary medical applications, equine racetrack vet 
erinarians have previously used an 8 mg tablet of guanabenZ, 
crushed and dissolved in Water, and injected the resultant 
solution intravenously into horses prior to racing. The ratio 
nale behind this administration is that it reduces the blood 
pressure in the horse’s pulmonary circulatory tract and 
thereby reduces the incidence and/or severity of exercise 
induced pulmonary hemorrhage (EIPH) in the horse. 
Current available sedatives and tranquilizers such as the 
aforementioned xylaZine and detomidine can produce side 
effects such as sinus bradychardia and ?rst or second degree 
atrioventricular block (Bohart G. Anesthesia of Horses in the 
Field in Current Therapy in Equine Medicine by Robinson 
N. E, 1998.). Therefor there exists a need in the art for a safe, 
effective oral, intravenous, or intramuscular compound for 
the standing sedation, tranquiliZation and analgesic effect of 
larger mammals that does not produce the adverse side 
effects seen With current sedatives/tranquilizers. 
Prior to the present invention guanidine derivatives, and 
in particular guanabenZ and its analogs, have not been 
reported as useful as a standing sedative, tranquiliZer and 
analgesic combination When used in horses and loWer mam 
mals at certain dosages. 
OBJECTS OF THE INVENTION 
Accordingly, it is an object of the invention to provide a 
veterinary composition in unit dosage form comprised of a 
guanidine derivative, e.g., guanabenZ acetate, for adminis 
tration to animals for the induction of a rapid onset and long 
lasting sedation and analgesia in the subject animal the 
effects of Which are capable of being selectively reversed. 
Another object of the invention, is to provide a method of 
producing a rapid onset and long lasting sedation and 
analgesia in an animal by administering in a single dose a 
pharmaceutically effective amount of a composition com 
prised of a guanidine derivative, e.g., guanabenZ acetate, to 
the subject animal. 
In particular, one object of the invention is to provide a 
composition and method for producing a rapid onset of 
sedation and analgesia in a standing animal, e.g., a large 
animal such as a horse, coW, sheep, pig, goat or the like that 
is selectively reversible. 
Likewise, another object of the invention is to provide a 
novel veterinary composition comprised of a derivative of 
the guanidine family of compounds, Wherein said derivative 
possesses 0t adrenergic receptor agonist activity, e.g., gua 
nabenZ acetate, for administration to animals for the induc 
tion of a rapid onset sedation and analgesia in the subject 
animal the effects of Which are capable of being selectively 
reversed. 
In particular, one object of the invention is to provide a 
composition and method for producing a rapid onset and 
long lasting sedation and/or analgesia in an animal Which is 
selectively reversible. 
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Another object of the invention is to provide a novel 
veterinary composition comprising an 0t adrenergic receptor 
agonist, e.g., a guanidine derivative, and method of use 
comprising a single administration of a pharmaceutically 
effective amount of said composition to thereby produce a 
rapid onset and longer lasting sedation and/ or analgesia in a 
standing large animal than is currently available to the 
veterinary medical profession and Which has selective 
reversibility. 
A further object of the invention is to provide a novel 
veterinary composition comprised of an 0t adrenergic recep 
tor agonist, e.g., a guanidine derivative, and method of use 
comprising a single administration of a pharmaceutically 
effective amount of said composition to thereby produce a 
rapid onset and longer lasting means for chemical restraint 
in a standing large animal than is currently available to the 
veterinary medical profession and Which has selective 
reversibility. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a plot of head ptosis response in a horse 
administered intravenous guanabenZ (100 mg, 0.2 mg/kg); 
FIG. 2 is a plot of rapid onset of analgesia response in a 
horse folloWing administration of intravenous guanabenZ 
(100 mg, 0.2 mg/kg); and 
FIG. 3 plots, in a horse administered intravenous guana 
benZ (100 mg, 0.2 mg/kg), (a) blood glucose levels (mg/D1); 
(b) urine production (ml); and (c) urine speci?c gravity. 
DETAILED DESCRIPTION OF THE 
INVENTION 
The present invention relates to a neW veterinary medical 
use for guanidine derivatives, e.g., guanabenZ and/or gua 
nabenZ acetate (an anti-hypertensive drug used in humans to 
control high blood pressure), Wherein the invention provides 
compositions thereof for producing a sedative, tranquiliZer 
and analgesic effect in primarily horses but also in other 
animal species. Thus, the present invention relates generally 
to novel compositions and methods of use for the guanidine 
family of compounds (guanidine derivatives), e.g., guana 
benZ and guanabenZ acetate, in providing a sedative, tran 
quiliZer and analgesic effect not only in horses but also loWer 
mammals by, e.g., intravenous injection of the aqueous 
solution of guanabenZ or a derivative thereof into the subject 
animal. 
As set forth in the teachings herein, guanabenZ and the 
related guanidine derivatives that possess 0t adrenergic 
receptor agonist effects have utility as safe, effective, long 
lasting and rapidly reversible sedatives and/or tranquiliZers 
and/or analgesics in other domestic animal species including 
but not limited to bovines, ovines, canines, and felines and 
other mammalian and domestic animal species requiring 
long acting, safe effective and rapidly reversible sedation 
and/or tranquiliZation and/or analgesia. 
Additional objects, advantages and other novel features of 
the invention Will be set forth in part in the description that 
folloWs and in part Will become apparent to those skilled in 
the art upon examination of the foregoing or may be learned 
With the practice of the invention. Certain patents and 
printed publications are cited throughout the instant speci 
?cation. The contents of these cited patents and printed 
publications are hereby incorporated herein in their entirety 
by reference. 
As used herein by “rapid onset” is meant to include the 
time interval from administration of the active, e.g., guana 
US 7,074,834 B2 
5 
benZ acetate, until the drug begins to take effect and produce 
the intended response, e.g., sedation and/or tranquiliZation 
and /or analgesia. For the compositions disclosed herein, this 
time interval typically ranges from betWeen about 1 minute 
to about 30 minutes. As one of skill in the art can appreciate, 
the length of time for onset of action can vary, e. g., depend 
ing upon the route of administration, the species, age, siZe, 
and health status of the animal and the like. In the adult 
horse, for example, the clinical signs of sedation Will begin 
to appear Within 143 minutes following a single intravenous 
administration of about 100 mg of guanabenZ or guanabenZ 
acetate. 
Likewise, by “sedation” is generally meant the act or 
process of calming or quieting an animal and may, in some 
instances be used synonymously With the term “tranquiliZa 
tion.” The term “tranquiliZation” as used herein generally 
means the act or process of depressing the function of the 
central nervous system, relieving anxiety and inducing a 
state of calmness in the conscious animal. 
The term “analgesia” or “analgesic” is meant to include 
any conscious relief from a painful stimulus in an animal. In 
general, an analgesic is an agent that alleviates pain or 
reduces the sensation of pain Without causing loss of con 
sciousness. The term “long lasting” is generally meant to 
include the time interval from the onset of effect of the active 
until the effect has Waned to a subclinical level. Thus, the 
establishment of this time interval is subjective but is readily 
ascertainable in the hands of the skilled artisan. Of course 
the duration of action of the active can vary, e. g., depending 
upon the route of administration, the species, age, siZe, and 
health status of the animal and the like. In the adult horse, 
for example, the clinical signs of sedation Will begin to 
appear Within 143 minutes folloWing a single intravenous 
administration of about 100 mg of guanabenZ or guanabenZ 
acetate and the duration of action is up to about 4 hours. 
The instant invention involves, in a preferred embodi 
ment, methods for the administration of a novel veterinary 
composition comprising a guanidine derivative, e.g., gua 
nabenZ acetate, in a pharmacutically effective amount by 
intravenous, intramuscular, oral or other administration to 
produce a rapid onset and long lasting sedation and analge 
sia. The compositions provided by the present invention are 
designed to overcome the shortcomings of currently avail 
able veterinary sedatives, tranquilizers or analgesics and 
provide a more effective and longer lasting sedation and/or 
analgesia and/or means of chemical restraint, the effects of 
Which may be rapidly reversed When desired. 
In one embodiment, the present invention provides the 
surprising discovery that guanabenZ acetate, after a single 
intravenous dose of about 0.2 milligrams per kilogram per 
horse, produces a rapid onset of sedation and/or, tranquil 
iZation and/or analgesia in the standing horse. After such a 
dose, profound sedation and head ptosis appear Within one 
minute and is maintained for up to four hours Which is of 
considerably longer longer duration than currently available 
0t arenergic receptor agonists, e.g., xalaZine and detomidine. 
This sedation and head ptosis response is rapidly reversible 
by intravenous administration of an alpha-2 adrenoceptor 
blocker (antagonist), e.g., yohimbine. 
These sedation and analgesic responses can be associated 
With a hyperglycemic response Which in turn causes an 
increased urine volume (diuresis) and a concomitant reduc 
tion in urine speci?c gravity. These pharmacological 
responses have not previously been described for guanabenZ 
or other guanidine derivatives in the horse, and they shoW 
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that this family of drugs has utility as a safe, effective long 
acting and rapidly reversible sedative, tranquiliZer and anal 
gesic in the horse. 
In line With the foregoing, it is Within the contemplation 
of the present invention to employ guanabenZ or a guanidine 
derivative as a sedative, tranquiliZer or analgesic. A deriva 
tive being quali?ed as a chemical substance derived from 
another substance either directly or by modi?cation or 
partial substitution. It is important that the guanidine deriva 
tive possess the requesite 0t adrenergic receptor agonist 
activity. Examples of other suitable guanidine derivatives 
include but are not limited to: 
GuanabenZ-2-[(2,6-dichlorophenyl)methylene] 
ecarboximidamide 
Guanadine sulfate-[2-(3 ,6-dihydro -4 -methyl- 1 (2H)-pyridyl) 
ethyl] guanidine sulfate 
Guanadrel-( l ,4-dioxaspiro [4,5] dec -2 -ylmethyl)guanidine 
sulfate 
Guanacydine-N"-cyano -N-(l , l -dimethylpropyl)guanidine 
Guanethidine- [2 -hexahydro -l (2H)-aZocinyl)ethyl] guani - 
dine 
Guanochlor sulfate-2-[2-(2,6-dichlorophenoxy)ethyl]hydra 
Zine carboximidamide sulfate 
GuanoxabenZ-2-[(2,6-dichlorophenyl)methylene] -N-hy 
droxyhydraZine carboximidamide 
Guanoxan sulfate-(2,3-dihydro- l ,4-benZodioxin-2 -ylm 
ethyl)guanidine 
In a similar manner, salts (any compound of a base or an 
acid) as Well as isomers (the possession by tWo or more 
distinct compounds of the same molecular formula, each 
molecule possessing an identical number of atoms of each 
element but in different arrangement) of the above men 
tioned compounds or other guanidine derivatives may be 
used in the compositions and methods provided by the 
invention. It is speci?cally contemplated that any pharma 
ceutically acceptable derivative of guanidine or the afore 
mentioned compounds are Within the scope of the invention 
as long as the derivative selected possesses su?icient 0t 
adrenergic receptor agonist activity. 
The present compositions may be administered by routes 
Well knoWn to those skilled in veterinary medicine ant the 
related arts. Therefore, although the guanabenZ for example, 
is conveniently administered intravenously, depending on 
the circumstances, the pharmaceutical composition may be 
administered, e.g., orally, intramuscularly, intravenously or 
by other routes knoWn to those skilled in this art. 
Compositions suitable for oral administration, include, 
e.g., suspensions, tablets, capsules, gels, pastes, boluses, or 
preparations in the form of poWders, granules, or pellets. 
Presently preferred orally administered compositions 
according to the invention can include suspensions and 
tablets and paste formulations. Alternatively, and presently 
preferred, as set forth herein, the compositions of the inven 
tion may be formulated for parenteral administration, e.g., 
by intramuscular, intraperitoneal, or intravenous injection. 
Pharmaceutically acceptable carriers present in the com 
positions of the present invention are materials recom 
mended for the purpose of administering the medicament in 
the desired dosage form. These may be liquid, solid, or 
gaseous materials, Which are otherWise inert or medically 
acceptable and are compatible With the active ingredients. 
The same applies for any added excipients, solvents of the 
active, buffers, preservatives and the like. 
For oral administration, ?ne poWders or granules may 
contain diluting agents, for example, calcium carbonate, 
calcium phosphate, mineral carriers, etc., disbursing and/or 
surface active agents, for example, polysorbates, and may be 
hydraZin 
US 7,074,834 B2 
7 
presented in a drench, in Water or in a syrup, in a bolus, 
paste, or in capsules or sachets in the dry state or in a 
non-aqueous suspension, or in a suspension in Water or 
syrup. Intravenous and intramuscular preparations may, e.g., 
include suitable solvents of the active and can include 
buffering agents, preservatives and the like. 
Where desirable or necessary, preserving, suspending, 
thickening or emulsifying agents can be included. If 
intended for oral use, a bolus can be provided for large 
animals With retention means to inhibit regurgitation. For 
example, it may be Weighed With a heavy density materials 
such as iron or tungsten or the like or may be retained by its 
shape, for example, by Wings Which spring after adminis 
tration. Boluses may contain disintegrating agents such as 
maiZe starch or calcium or sodium methylcelluloses, 
hydroxypropylmethylcellulose, guar based vegetable gums, 
sodium alginates or sodium starch glycolates; granulating or 
binding agents, such as starch in the form of mucilage, starch 
derivatives, such as methylcellulose, calcium stearate, talc, 
gelatin or polyvinylpyrrolidone; and/or lubricating agents, 
such as magnesium stearate or stearic acid. 
Other compounds Which may be included are, for 
example, medically inert ingredients, e.g. solid and liquid 
diluents, such as starch or calcium phosphate for tablets, 
boluses or capsules; olive oil or ethyl oleate for soft cap 
sules; and Water or vegetable oil for suspensions or emul 
sions; lubricating agents such as talc or magnesium stearate; 
gelling agents such as colloidal clays; thickening agents 
such as gum tragacanth or sodium alginate; dedusting agents 
such as liquid paraf?n, ?xed oils and surfactants and other 
therapeutically acceptable accessory ingredients, such as 
humectants, preservatives, buffers, and anti-oxidants, Which 
are useful as carriers in such formulations. When desired, 
other medicaments and/ or nutrients, unless contraindicated, 
may also be included. 
It is also to be understood that While the preferred 
formulation is formulated in unit dosage form for a single 
administration, alternatively, the compositions of the inven 
tion may be given to effect (to achieve a desired level of 
sedation and/ or analgesia), administered in divided doses, or 
supplemental doses administered as needed. 
In particular, one embodiment of the present invention 
provides a veterinary composition comprising a pharmaceu 
tically effective amount of a pharmaceutically acceptable 
guanidine derivative Which is useful for providing a rapid 
onset and long lasting analgesia and/or sedation in an 
animal. As set forth above, the guanidine derivative can be 
any of the afore-mentioned compounds or other derivatives 
of guanidine provided that the selected active possesses 
su?icient 0t adrenergic receptor agonist activity to be used in 
accordance With the methods of the invention and provided 
that the selected active does not produce unWanted side 
effects in the subject animal Which will affect the long term 
health of the animal. 
In a preferred embodiment, the invention provides a 
composition Wherein the guanidine derivative is selected 
from the group consisting of guanabenZ, guanabenZ acetate, 
guanoxabenZ, clonidine, guanacline, guanadrel, guanaZod 
ine, guanethidine, guanfacine and guanochlor, guanoxan, 
and mixtures thereof. In yet another embodiment, the pre 
ferred guanidine derivative is guanabenZ, guanabenZ acetate 
or pharmaceutically acceptable derivatives thereof. 
Of course, one of skill in the art can appreciate that the 
compositions of the invention can further comprise a phar 
maceutically acceptable carrier and speci?c embodiments 
thereof are hereby provided. LikeWise, the present invention 
provides speci?c embodiments Wherein the veterinary com 
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position comprised of a pharmaceutically effective amount 
of a guanidine derivative is specially adapted for oral, 
intramuscular or intravenous administration. As set forth 
above, it can be appreciated by the skilled artisan that the 
compositions set forth herein can be formulated for and 
adapted for use in any species of animal, including, but not 
limited to equine, canine, feline, bovine, caprine, porcine 
and ovine species. 
In one preferred embodiment, the invention provides a 
veterinary composition comprising a pharmaceutically 
effective amount of a guanidine derivative, e.g., guanabenZ 
or guanabenZ acetate, Which useful for providing a rapid 
onset and long lasting analgesia and sedation in a standing 
animal, e.g., a horse. As set forth in the examples beloW, the 
rapid onset and lasting duration of a single intravenous 
administration of the active provides a novel and heretofore 
unreported use for this family of compounds. 
A particularly attractive feature of the compositions pro 
vided by the invention is that the analgesia and sedation 
produced by administration of the active are rapidly revers 
ible. In particular, one embodiment of the invention provides 
a method for selective reversal of the analgesic, and/or 
tranquil and/or sedative effects via administration of a 
pharmaceutically effective amount of an 0t adrenergic 
antagonist. Examples of suitable 0t adrenergic antagonists, 
include but are not limited to yohimbine, rauWolscine, 
idaZoxan, tolaZoline and atepameZole. 
In a presently preferred embodiment, the ot adrenergic 
antagonist suitable for reversal of the active is yohimbine or 
tolaZoline. A presently preferred dosage of yohimbine for 
reversal of the active guanidine derivative is betWeen about 
0.04 to about 0.08 mg/kg IV. and the preferred dosage of 
tolaZoline is betWeen about 2.0 to about 4.0 mg/kg I.V. One 
of skill in the art can appreciate that the dosage of the 
reversal agent Will vary depending upon, e.g., the length of 
time from administration of the active, the dosage and route 
of administration, the species of animal, siZe and health of 
the animal and the like. 
In a presently preferred embodiment, the invention pro 
vides a veterinary composition comprised of a pharmaceu 
tically effective amount of a guanidine derivative that is 
useful for providing a rapid onset and long lasting analgesia 
and sedation in an animal Wherein the pharmaceutically 
effective amount is betWeen about 0.05 mg/kg and about 
0.50 mg/kg. The compositions of the invention can be 
formulated in unit dosage form, e.g., in an oral tablet 
formulated on a preferred administration rate for a particular 
species of animal or in injectaable an form, e.g., the selected 
active in a 1 mg/ml solution. In a presently preferred 
embodiment, the pharmaceutically effective amount of the 
quanidine derivative is about 0.25 mg/kg. In a particularly 
preferred embodiment the compositions of the invention are 
comprised of a guanidine derivative that is guanabenZ, 
guanabenZ acetate or a pharmaceutically acceptable deriva 
tive thereof and the pharmaceutically effective amount is 
betWeen about 0.05 mg/kg and about 0.50 mg/kg, but is 
especially about 0.25 mg/kg. 
The present invention also provides for methods of induc 
ing a rapid onset and long lasting sedation and/or analgesia 
in an animal. The methods comprise administering to the 
animal a pharmaceutically effective amount of a composi 
tion comprised of a guanidine derivative. As set forth above 
With reference to the compositions of the invention, the 
guanidine derivative can be any derivative of the guanidine 
family so long as the selected derivative possesses the 
requisite 0t adrenergic receptor agonist activity to produce 
the desired clinical effects in the animal Without causing 
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undue side effects. Examples of suitable guanidine deriva 
tives include, but are not limited to guanabenZ, guanabenZ 
acetate, guanoxabenZ, clonidine, guanacline, guanadrel, 
guanaZodine, guanethidine, guanfacine and guanochior, 
guanoxan and mixtures thereof. The presently preferred 
methods of the invention comprise of inducing a rapid onset 
and long lasting sedation and/or analgesia in an animal. The 
methods comprise administering to the animal a pharma 
ceutically e?fective amount of guanabenZ, guanabenZ acetate 
or pharmaceutically acceptable derivatives thereof. 
One of skill in the art Will appreciate that the adminis 
tering step provided by the invention can be via any route, 
including but not limited to oral, intravenous and intramus 
cular. Further, the methods provided herein are contem 
plated for use on any animal, including but not limited to 
equine, canine, feline, bovine, caprine, porcine and ovine. In 
a particularly preferred embodiment of the methods of the 
invention the animal is a large animal, e. g., a horse or a coW, 
and the sedation and analgesia are induced and maintained 
While the animal is standing. 
The compositions comprised of guanidine derivatives 
administered according to the methods of the invention are 
administered in pharmaceutically e?fective amounts Which 
can range from betWeen about 0.05 mg/kg and about 0.50 
mg/kg of the active. In one preferred embodiment, the 
pharmaceutically e?fective amount of the guanidine deriva 
tive is about 0.25 mg/kg. 
A presently preferred method of the invention, comprises 
inducing a rapid onset and long lasting sedation and/or 
analgesia in an animal, comprising administering to the 
animal a pharmaceutically e?fective amount of a composi 
tion comprised of guanabenz, guanabenZ acetate or phar 
maceutically acceptable derivatives thereof and Wherein the 
pharmaceutically e?fective amount is betWeen about 0.05 
mg/kg and about 0.50 mg/kg but is especially about 0.25 
mg/kg. 
Of particular importance With respect to the methods for 
providing long lasting sedation and/ or tranquiliZation and/or 
analgesia set forth herein is the fact that the method further 
provides the ability for selectively reversing or controlling 
the level of analgesia and/or sedation and/or tranquiliZation 
in the animal. The methods of the invention can therefore 
further comprise the step administering a pharmaceutically 
e?fective amount of 0t adrenergic receptor antagonist to the 
animal to control or reverse the e?fects of the previously 
administered 0t adrenergic receptor agonists. The 0t adren 
ergic receptor antagonists suitable for use in the invention 
include, but are not limited to yohimbine, rauWolseine, 
idaZoxan and atepameZole. Presently preferred 0t adrenergic 
receptor antagonists are yohimbine or tolaZoline. Apresently 
preferred dosage of yohimbine for reversal of the active 
guanidine derivative administered according to the methods 
set forth herein is betWeen about 0.04 to about 0.08 mg/kg 
IV. and the preferred dosage of tolaZoline is betWeen about 
2.0 to about 4.0 mg/kg I.V. One of skill in the art can 
appreciate that the dosage of the reversal agent Will vary 
depending upon, e.g., the length of time from administration 
of the active, the dosage and route of administration, the 
species of animal, siZe and health of the animal and the like. 
One of skill in the art can also appreciate that the 
compositions and methods of the invention have many 
applications and uses in the ?eld of veterinary medicine. In 
addition to providing a means for chemical restraint of 
animals, particularly large animals, the compounds may be 
used in situations Whenever analgesia and/or sedation are 
required. In the equine species for example, the composi 
tions of the invention may be used to treat any source of pain 
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but may be especially useful in alleviating or lessening the 
pain associated With colic (abdominal pain). LikeWise, the 
pain assocaited With acute racing injury and/ or post surgical 
pain may be treated via the compositions disclosed herein. 
A further appreciation of the invention may be gleaned 
from the folloWing speci?c examples. These speci?c 
examples are provided for illustration only and are not to be 
regarded as restricting the invention in any Way. 
EXAMPLES 
Example 1 
GuanabenZ Produces a Rapid Onset of TranquliZation and 
Sedation: 
As shoWn in FIG. 1, a horse (about 1000 lbs), Was 
administered guanabenZ at a dose of 0.2 mg/kg (100 mg) 
intravenously at time point 0. Note hoW the dose of 100 mg 
of guanabenZ yields a very rapid onset of analgesia response 
as indicated by the decrease in head ptosis of the horse. The 
solid circles (O - - - O) shoW head ptosis measured as cm 
above ground level after rapid intravenous administration of 
guanabenZ. Note also the rapid reversal of this tranquiliZa 
tion and sedation by the administration of yohimbine (see 
arroW) at a dose of 60 mg intravenously. The open circles 
(0 - - - 0) shoW the rapid reversal e?fect by intravenous 
injection of yohimbine. 
The advantages of this approach are many fold: In the ?rst 
place, e?fective sedative and tranquiliZing levels of guana 
benZ or a derivative thereof are attained Within minutes of 
the administration of the compound, Which leads to shorter 
Waiting time to initiate desired procedure or treatment. In the 
second place, the animal Will remain in a standing position. 
Thirdly, the duration of the sedation and tranquiliZation lasts 
for an extended period of time, enabling the performance of 
lengthier procedures or treatments. Fourthly, the sedative 
and tranquiliZing e?fect of guanabenZ or derivatives thereof 
can be rapidly reversed by the administration of yohimbine 
or any other alpha-2-adreno receptor antagonist. 
Example 2 
Analgesic Response to GuanabenZ in the Horse: 
A horse (1000 lbs) in Was administered guanabenZ at a 
dose of 0.2 mg/kg (100 mg) intravenously at time point 0 
(see FIG. 2). Note hoW the dose of 100 mg of guanabenZ 
yields a very rapid onset of analgesia response as indicated 
by the increase in desensitiZation to the heat lamp. Note also 
that this response is maintained at full intensity for approxi 
mately 30 minutes and declines thereafter, and returns to 
control values by 6 hrs post administration. The solid circles 
(O - - - O) shoW the increasing control latency in our heat 
lamp equine analgesia model after administration of guana 
benZ at indicated Zero time. 
Example 3 
GuanabenZ IV Produces a Transient Diuresis With a Corre 
sponding Reduction in Urinary Speci?c Gravity and Tran 
sient Hyperglycemia and Glucosuria: 
Referring noW to FIG. 3, a horse (about 1000 lbs) Was 
administered guanabenZ at a dose of 0.2 mg/kg (100 mg) 
intravenously at time point 0. In FIG. 3a, note hoW the dose 
of 100 mg of guanabenZ yields a transient increase in blood 
glucose levels after the administration of guanabenZ. The 
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solid circles (. - - - .) show blood glucose levels after rapid 
intravenous administration of guanabenZ. Note also the 
increase in urine glucose levels after the administration of 
guanabenZ. The open circles (CD-0) shoW the correspond 
ing urinary concentrations of glucose after this administra 
tion. 
In FIG. 3b, note hoW the dose of 100 mg of guanabenZ 
yields an increase in urine production as indicated by the 
increase in volume of urine collected. The solid circles 
(. - - - .) shoW volume of urinary output after rapid 
intravenous administration of guanabenZ. Note also in FIG. 
30, the decrease in speci?c gravity of the urine after the 
administration of the guanabenZ. The solid circles (. - - - .) 
shoW the corresponding urinary speci?c gravity values after 
this administration. 
The foregoing description of a preferred embodiment of 
the invention has been presented for purposes of illustration 
and description. It is not intended to be exhaustive or to limit 
the invention to the precise form disclosed. Obvious modi 
?cations or variations are possible in light of the above 
teachings. The embodiment Was chosen and described to 
provide the best illustration of the principles of the invention 
and its practical application thereby enable one of ordinary 
skill in the art to utiliZe the invention in various embodi 
ments and With various modi?cations and variations are 
Within the scope of the invention as determined by the 
appended claims When interpreted in accordance With the 
breadth to Which they are fairly, legally and equitable 
entitled. 
What is claimed is: 
1. A method of inducing rapid onset and long lasting 
sedation and analgesia in an animal, comprising adminis 
tering to the animal a pharmaceutically effective amount of 
a composition consisting essentially of a guanidine deriva 
tive selected from the group consisting of guanabenZ, gua 
nabenZ acetate, guanoXabenZ, clonidine, guanacline, guana 
drel, guanaZodine, guanethidine, guanfacine, guanochior, 
and guanoxan. 
2. The method of claim 1, Wherein the guanadine deriva 
tive is guanabenZ acetate or pharmaceutically acceptable 
derivative thereof. 
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3. The method of claim 1, Wherein the administration is 
oral. 
4. The method of claim 1, Wherein the administration is 
intravenous . 
5. The method of claim 1, Wherein the administration is 
intramuscular. 
6. The method of claim 1, Wherein the animal is selected 
from the group consisting of equine, canine, feline, bovine, 
caprine, porcine and ovine. 
7. The method of claim 1, Wherein the animal is an equine. 
8. The method of claim 1 Wherein the rapid onset sedation 
and analgesia is induced in a standing animal. 
9. The method of claim 1, further comprising the step of 
selectively reversing or controlling the level of analgesia and 
sedation in the animal comprising administering a pharma 
ceutically effective amount of 0t adrenergic antagonist to the 
animal. 
10. The method of claim 9 Wherein the ot adrenergic 
antagonist is selected from the group consisting of yohim 
bine, rauWolscine, idaZoxan and atepameZole. 
11. The method of claim 1, Wherein the pharmaceutically 
effective amount of the guanidine derivative is betWeen 
about 0.05 mg/kg and about 0.50 mg/kg. 
12. The method of claim 1, Wherein the pharmaceutically 
effective amount of the guanidine derivative is about 0.25 
mg/kg. 
13. The method of claim 1, Wherein the guanidine deriva 
tive is guanabenZ acetate or a pharmaceutically acceptable 
derivative thereof and the pharmaceutically effective 
amount is betWeen about 0.05 mg/kg and about 0.50 mg/kg. 
14. The method of claim 1, Wherein the guanidine deriva 
tive is guanabenZ acetate or a pharmaceutically acceptable 
derivative thereof and the pharmaceutically effective 
amount is about 0.25 mg/kg. 
15. The method of claim 1, Wherein the guanidine deriva 
tive is an 0t adrenergic agonist. 
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